Camidge DR et al. Brigatinib versus crizotinib in advanced ALK inhibitor-naive ALK-positive non-small cell lung cancer: Second interim analysis of the phase III ALTA-1L trial. J Clin Oncol 2020;JCO2000505. Abstract
Camidge DR et al. Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non-small cell lung cancer in the global phase III ALEX study. J Thorac Oncol 2019;14(7):1233-43. Abstract
Camidge DR et al. Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer. N Engl J Med 2018;379(21):2027-39. Abstract
Dimou A et al. Dramatic response to lorlatinib in a patient with CD74-ROS1-positive lung adenocarcinoma with acquired F2004V mutation. JCO Precis Oncol 2019;3:PO.19.00013. Abstract
Gainor JF et al. Patterns of metastatic spread and mechanisms of resistance to crizotinib in ROS1-positive non-small-cell lung cancer. JCO Precis Oncol 2017;2017:PO.17.00063. Abstract
Gainor JF et al. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discovery 2016;6(10):1118-33. Abstract
Le A et al. Unveiling hidden MET-mediated primary alectinib resistance in ALK-positive non-small cell lung cancer. IASLC 2019;Abstract P1.14-09.
Lin JJ et al. Long-term efficacy and outcomes with sequential crizotinib followed by alectinib in ALK+ NSCLC. ASCO 2018;Abstract 9093.
Patil T et al. The incidence of brain metastases in stage IV ROS1-rearranged non-small cell lung cancer and rate of central nervous system progression on crizotinib. J Thorac Oncol 2018;13(11):1717-26. Abstract
Peters S et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med 2017;377(9):829-38. Abstract
Shaw AT et al. Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: A multicentre, open-label, single-arm, phase 1-2 trial. Lancet Oncol 2019;20(12):1691-701. Abstract
Simons EA et al. Variation in toxicity reporting methods for early phase lung cancer treatment trials at oncology conferences. J Thorac Oncol 2020;15(9):1425-33. Abstract
Solomon B et al. Lorlatinib vs crizotinib in the first-line treatment of patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC): Results of the phase III CROWN study. ESMO 2020;Abstract LBA2.